Skip to content

Levobupivacaine to the Surgical Wound Following Cesarean

Efficacy of Continuous Infusion of Levobupivacaine to the Surgical Wound Following Cesarean

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01458431
Enrollment
70
Registered
2011-10-24
Start date
2011-10-31
Completion date
2014-09-30
Last updated
2014-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

cesarean section, wound infusion, Local anesthetic levobupivacaine, Pain management

Brief summary

The postoperative period following cesarean is associated with moderate to severe pain that requires a considerable amount of analgesics that carry with them side-effects such as nausea, vomiting, fatigue and immobilization. Several studies have tried, with variable results, to find a more effective analgesia alternative such as infusion of local anesthetics through a catheter in the surgical wound sinus, a practice that has currently been widely used in clinical practice. Despite existing references on its use in the postoperative period following cesareans there continues to be a lack of information on other aspects. The investigators study hypothesis is that the use of levobupivacaine in the surgical wound will reduce the surface of hyperalgesia compared to the control group.

Interventions

DRUGLevobupivacaine

continuous levobupivacaine subfascial infusion

DRUGNaCl

continuous NaCl subfascial infusion

Sponsors

Manuel Ángel Gómez-Ríos
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Full-term pregnant women who undergo scheduled cesarean surgery under intradural anesthesia. * Duly informed patients who have signed the informed consent during the preanesthesia consultation, or after a period of consideration if necessary, expressing their consent to be included in the study. * Between 18-45 years of age. * ASA I and II. * Sufficient intellectual ability to understand the technique as well as the equipment being used.

Exclusion criteria

* Failure to meet any of the above criteria. * Presence of a major medical, cardiovascular, pulmonary, metabolic, renal or liver disorder. * Preeclampsia and/or HELLP syndrome. * Coagulopathy * Profuse bleeding greater than 1000 ml or that which provokes hemodynamic instability that requires aggressive fluid therapy and/or transfusion. * Allergy to any drug included in the protocol. * Psychiatric or neurological pathology. * Preexisting infection. * Previous treatment with opioids or antidepressants or suffer from chronic pain. * History of alcohol or drug abuse or known consumption of medications that interfere with LB metabolism.

Design outcomes

Primary

MeasureTime frame
Area of incisional secondary hyperalgesia72 hours

Secondary

MeasureTime frameDescription
consumption of morphine (mg) and paracetamol (gr)48 hours
Incidence of chronic pain6 month
Pharmacokinetic variables of levobupivacaine72 hoursCmax, Area Under Curve, Tmax
Pain relief72 hours
Rate of satisfaction experienced by the patients through a survey72 hours
endocrin-metabolic response72 hours
Incidence of complications and/or side effects related to the technique72 hours

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026